Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure

Breast Cancer Research and Treatment

Volumn 87, Issue 2, 2004, Pages 181-188

  Vehmanen, Leena ^a   Saarto, Tiina ^a   Risteli, Juha ^b   Risteli, Leila ^b   Blomqvist, Carl ^a   Elomaa, Inkeri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

adjuvant chemotherapy; biphosphonates; bone loss; breast cancer; clodronate

Indexed keywords

BIOCHEMICAL MARKER; CLODRONIC ACID; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BONE TURNOVER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; EARLY CANCER; FEMALE; HUMAN; INVOLUTIONAL OSTEOPOROSIS; LUMBAR SPINE; OSTEOLYSIS; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; ANTIMETABOLITES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE RESORPTION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; METHOTREXATE; MIDDLE AGED; OVARIAN FAILURE, PREMATURE; PREMENOPAUSE;

EID: 4544349095     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000041624.00665.4e     Document Type: Article

References (43)

1. Genant HK, Cann CE, Ettinger B, Gordan GS: Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97: 699-705, 1982
2. Richelson LS, Wahner HW, Melton LJ III, Riggs BL: Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311: 1273-1275, 1984
3. Pouilles JM, Tremollieres F, Bonneu M, Ribot C: Influence of early age at menopause on vertebral bone mass. J Miner Res 9: 311-315, 1994
4. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14: 1718-1729, 1996
5. Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15: 1341-1347, 1997
6. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322: 1265-1271, 1990
7. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323: 73-79, 1990
8. Giannini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, Liberto L, Nobile M, Crepaldi G: Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14: 137-141, 1993
9. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III: Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95: 557-567, 1993
10. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoni C, Cristallini S: Cyclic clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 10: 697-703, 1995
11. Filipponi P, Cristallini S, Rizzello E, Policani G, Fedeli L, Gregorio F, Boldrini S, Troiani S, Massoni C: Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone 18: 179-184, 1996
12. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443, 1995
13. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genent HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541, 1996
14. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results of the fracture intervention trial. JAMA 280: 2077-2082, 1998
15. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282: 1344-1352, 1999
16. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY: Hip intervention Progran Study Group. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 344: 333-340, 2001
17. Vehmanen L, Saarto T, Elomaa I, Mäkelä P, Välimäki M, Blomqvist C: Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in pre-menopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37: 2373-2378, 2001
18. Saarto T, Vehmanen L, Elomaa I, Välimäki M, Mäkelä P, Blomqvist C: The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 84: 1047-1051, 2001
19. Elomaa I, Blomqvist C, Gröhn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrom T: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1: 146-149, 1983
20. Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F, Pannuti F: Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast cancer metastasizing to skeleton. Oncology 48: 97-101, 1991
21. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65, 1993
22. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11: 491-498, 1993
23. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM: Delay in progression of bone metastases in beast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14: 2552-2559, 1996
24. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16: 2038-2044, 1998
25. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17: 846-854, 1999
26. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998
27. Saarto T, Blomqvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19, 10-17, 2001
28. Powles TJ, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219-3224, 2002
29. Riis BJ, Johansen J, Christiansen C: Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. Maturitas 10: 51-58, 1988
30. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD: Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 72: 367-373, 1991
31. Bonde M, Qvist P, Fledelius C, Riis BJ, Cristiansen C: Applications of an enzyme immunoassay for a new marker of bone resorption (cross laps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80: 864-868, 1995
32. Bjarnason NH, Christiansen C: Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 26: 551-552, 2000
33. Watts NB, Nolan JC, Brennan JJ, Yang HM: Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study. Menopause 7: 375-382, 2000
34. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79: 1693-1700, 1994
35. Pedrazzoni M, Alfano F, Gatti C, Fantuzzi M, Girasole G, Campanini C, Basini G, Passeri M: Acute effects of biphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 57: 25-29, 1995
36. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y. Souberbielle JC: Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporosis International 11: 295-303, 2000
37. Watts NB, Jenkins DK, Visor JM, Casal DC, Geusens P: Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate. Osteoporosis International 12: 279-288, 2001
38. Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S, Elomaa I: Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and postmenopausal non metastatic breast cancer patients. Br J Cancer 78: 240-245, 1998
39. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J: Immunoassay for the intact aminoterminal propeptide of human type I procollagen (PINP). Clin Chem 42: 947-954, 1996
40. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L: Radioimmunoassay for the pyridoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39: 635-640, 1993
41. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. BJC 72: 1289-1293, 1995
42. Atula ST. Tahtela RK, Nevalainen JI, Pylkkanen LH: Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia. Acta Oncol 42: 735-740, 2003
43. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558-567, 2001